Sanofi and Regeneron Pharmaceuticals faced notable share price declines after mixed results from late-stage clinical trials of their experimental drug, itepekimab, targeting chronic obstructive pulmon...

Sanofi SA $SNY, a leading global pharmaceutical company, has published its financial results for the first quarter, which have proven to be quite encouraging. High demand for its popular drug Dupixent...